Luzanov V M, Rogacheva S A, Shagalov L B, Vaĭnberg Iu P
Biull Eksp Biol Med. 1982 Jan;93(1):84-7.
CBA male mice received myelosan intraperitoneally in a dose of 10 mg/kg weekly for 5 weeks. One day after the second myelosan injection, the animals were given high-molecular DNA once a week for 9 weeks. DNA preparations were obtained from the milt of sturgeon fish. Heterologous DNA was shown to change the rate of hypoplasia development during myelosan administration and to affect the completeness of hemopoiesis recovery during discontinuation of cytostatic injections. This was determined by the action of the biopolymer on the colony-forming units and on differentiated myelokaryocytes. The action of DNA on hemopoiesis in mice with cytostatic hypoplasia affected the animals' survival. In the course of the observation period, the death in the group of untreated mice constituted 68%, while that in the group of treated animals to 20%.
CBA雄性小鼠每周腹腔注射10毫克/千克的美法仑，持续5周。在第二次注射美法仑一天后，每周给动物注射一次高分子量DNA，持续9周。DNA制剂取自鲟鱼的脾脏。结果显示，异源DNA可改变美法仑给药期间发育不全的发生率，并影响停止细胞抑制注射后造血恢复的完整性。这是由生物聚合物对集落形成单位和分化的骨髓核细胞的作用所决定的。DNA对细胞抑制性发育不全小鼠造血功能的影响关乎动物的存活。在观察期内，未治疗小鼠组的死亡率为68%，而治疗动物组的死亡率为20%。
